182 related articles for article (PubMed ID: 22360487)
1. Non-alcoholic steatohepatitis: what can we learn from animal models?
Almonacid-Urrego CC; Sánchez-Campos S; Tuñón MJ; González-Gallego J
Curr Med Chem; 2012; 19(9):1389-404. PubMed ID: 22360487
[TBL] [Abstract][Full Text] [Related]
2. Animal models of NASH: getting both pathology and metabolic context right.
Larter CZ; Yeh MM
J Gastroenterol Hepatol; 2008 Nov; 23(11):1635-48. PubMed ID: 18752564
[TBL] [Abstract][Full Text] [Related]
3. Commonly used animal models of non-alcoholic steatohepatitis.
Fan JG; Qiao L
Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):233-40. PubMed ID: 19502161
[TBL] [Abstract][Full Text] [Related]
4. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Soejima Y; Fukusato T
World J Gastroenterol; 2012 May; 18(19):2300-8. PubMed ID: 22654421
[TBL] [Abstract][Full Text] [Related]
5. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
6. [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
[TBL] [Abstract][Full Text] [Related]
7. Metabolic disturbances in non-alcoholic fatty liver disease.
Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
[TBL] [Abstract][Full Text] [Related]
8. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
9. A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model.
Okamoto K; Koda M; Okamoto T; Onoyama T; Miyoshi K; Kishina M; Kato J; Tokunaga S; Sugihara TA; Hara Y; Hino K; Murawaki Y
PLoS One; 2016; 11(5):e0154676. PubMed ID: 27135827
[TBL] [Abstract][Full Text] [Related]
10. Animal models of non-alcoholic steatohepatitis: of mice and man.
Schattenberg JM; Galle PR
Dig Dis; 2010; 28(1):247-54. PubMed ID: 20460919
[TBL] [Abstract][Full Text] [Related]
11. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats.
Nakano T; Cheng YF; Lai CY; Hsu LW; Chang YC; Deng JY; Huang YZ; Honda H; Chen KD; Wang CC; Chiu KW; Jawan B; Eng HL; Goto S; Chen CL
J Hepatol; 2011 Aug; 55(2):415-25. PubMed ID: 21184788
[TBL] [Abstract][Full Text] [Related]
12. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
13. Murine models provide insight to the development of non-alcoholic fatty liver disease.
Reid DT; Eksteen B
Nutr Res Rev; 2015 Dec; 28(2):133-142. PubMed ID: 26494024
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
15. Animal Models of Non-alcoholic Fatty Liver Diseases and Its Associated Liver Cancer.
Lau JKC; Zhang X; Yu J
Adv Exp Med Biol; 2018; 1061():139-147. PubMed ID: 29956212
[TBL] [Abstract][Full Text] [Related]
16. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease.
Souza MR; Diniz Mde F; Medeiros-Filho JE; Araújo MS
Arq Gastroenterol; 2012; 49(1):89-96. PubMed ID: 22481692
[TBL] [Abstract][Full Text] [Related]
17. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis.
Dongiovanni P; Romeo S; Valenti L
Biomed Res Int; 2015; 2015():460190. PubMed ID: 26273621
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic steatohepatitis: new insights from OMICS studies.
Martel C; Esposti DD; Bouchet A; Brenner C; Lemoine A
Curr Pharm Biotechnol; 2012 Apr; 13(5):726-35. PubMed ID: 22122481
[TBL] [Abstract][Full Text] [Related]
19. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances.
Lau JK; Zhang X; Yu J
J Pathol; 2017 Jan; 241(1):36-44. PubMed ID: 27757953
[TBL] [Abstract][Full Text] [Related]
20. Animal models of NAFLD from the pathologist's point of view.
Denk H; Abuja PM; Zatloukal K
Biochim Biophys Acta Mol Basis Dis; 2019 May; 1865(5):929-942. PubMed ID: 29746920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
